Contact
Please use this form to send email to PR contact of this press release:
Kadmon Corporation Initiates Phase 2 Clinical Trial Evaluating Tesevatinib in Non-Small Cell Lung Cancer With Activating EGFR Mutations and Brain Metastases or Leptomeningeal Disease
TO: